cerrar
Tagged with VAT

Hot Topics in Belgian Pharma
In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at…

Anne-Laure Dreno – Country President, AstraZeneca Belgium…
Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the…

China’s Regulatory Reform and its Contribution to Global…
Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) highlights the leaps and bounds with which…

New UAE Pharma Report April 2020 Out Now
PharmaBoardroom's latest country report gives an up-to-date and comprehensive overview of one of the most strategic and innovation-friendly nations on…

Miguel Forte – CEO, Bone Therapeutics, Belgium
Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the…

Brigitte Nolet – Country Manager, Roche Belgium &…
Brigitte Nolet, country manager of Roche for Belgium and Luxembourg, speaks about her transition to the Belgian market and her priorities for leading…

Sweden: An Innovation Nation
Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European…

Christos Andriopoulos – Managing Director, Merck Belgium…
Christos Andriopoulos, managing director of Merck, speaks about his experience transitioning from global operations to leading a country subsidiary.…

The UK: The G7’s Hottest Life Science Investment Destination?
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as…

Fernando J Cruz – Country President, Novartis Mexico
Novartis Mexico Country President Fernando Cruz outlines the new normal for Mexican healthcare post-regulatory reform, how the company’s global…

China: A New Decade
2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese…

Would the Last Pharmaceutical Investor in Europe Please Turn the…
EFPIA’s Nathalie Moll highlights how Europe can reverse its decline in the global medical research standings and once again make the continent a…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here